Home > Donors’ Advisory Committee

Donors’ Advisory Committee

Appointed by the Executive Committee according to advice and support requirements. Appointment duration is dependent on Advisory Committee needs and individual availability.

Chair – Mr. Patrick Tippoo, Biovac, South Africa
Mr. Patrick Tippoo is Head of Science & Innovation at Biovac. He has been with Biovac since its inception in 2003. Patrick’s responsibilities include strategic alliances and local & international partnering, product development and inbound and outbound product development technology transfer partnerships. He is a founding member and current Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and has been a member of the DCVMN Executive Committee since 2014.
Member – Mr. Adriansjah Azhari, Biofarma, Indonesia
Mr. Azhari joined Biofarma in 1989 and has extensive experience in biotechnology and Quality Management including Good Manufacturing Practices. He is currently a member of the Board of Executives of Biofarma as Senior Executive Vice President overseeing Research and Development activities. His previous appointments in the company were Head of Business Planning and Strategy, Head of Quality Assurance / Responsible Pharmacist, Head of bacterial vaccines production and Head of formulation/filling/packaging. Mr Azhari is a pharmacist and holds a Master’s degree in Operations Management.
Member – Mr. Jong Ho Park, LG Chem, South Korea
Mr. Jongho Park is Director of the Overseas Sales Department in LG Chem. He joined the business support team of LG Chem in 1995. After 10 years of experience in developing and implementing a sales force effectiveness program for the domestic market, he moved to the overseas business team, becoming team leader in 2011. He then moved to the vaccine sales team as team leader in 2016, specializing in vaccines. After the Vaccine Business Division merged with the Specialty Drug Business Division, and he was promoted to Director of the Overseas Sales Department, in 2019, responsible for the leadership and overall management of overseas sales for vaccines, fertility treatment drugs, diagnostics and veterinary products. Mr Park has a Bachelor’s degree from Sungkyunkwan University in Korea, majoring in Genetic Engineering.
Member – Dr. Shaozhong Dong, Institute of Medical Biology, Chinese Academy of Medical Sciences, China
Dr. Dong is Vice Director of the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS). In the capacity of Principal Investigator, he has been responsible for research on human vaccines, including recombinant Hepatitis E, new adjuvant hepatitis B vaccine and rabies vaccine. Dr. Dong graduated from Kunming Medical College in 1990 and received his PhD of science in Peking Union Medical College in 2003. He trained as a postdoctoral fellow at Emory University in USA.
Member – Dr. David Kaslow, PATH, USA
Dr. Kaslow is Vice President for Essential Medicines at PATH, which includes the Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). Before joining PATH in 2012, he held key advisory positions with PATH’s Malaria Vaccine Initiative (MVI) and the Bill & Melinda Gates Foundation. Dr. Kaslow previously worked at Merck, Vical and NIAID in research and product development roles. He studied biochemistry at University of California, Davis, and medicine at University of California, San Francisco.
Member – Ray Prasad, Bill & Melinda Gates Foundation, USA
Mr. Prasad is Senior CMC Advisor in Vaccine Development, Global Health. Before joining The Foundation, Mr. Prasad was COO and President, Vaccines & Biologics at Biological E and a board member for Qualivax, a GSK-BE joint venture. Mr. Prasad’s 40 years of experience include senior roles at Genentech, Chiron Novartis, Medimmune and Genzyme.
Member - Professor Robin Shattock, Professor of Mucosal Infection and Immunity, Imperial College
Professor Shattock is Head of Mucosal Infection and Immunity, Department of Medicine, Imperial College, London. His research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 160 peer reviewed articles in this area.
Member (Alternate) – Dr Benjamin Pierce, Future Vaccine Manufacturing Hub, Imperial College, London
Dr. Pierce is Operations Manager for the Future Vaccine Manufacturing Research Hub, Imperial College London, directed by Prof Robin Shattock. The FVMR Hub is committed towards researching innovative and more cost-effective vaccines for populations in developing countries and includes 8 leading UK-based institutes as well as grantees laboratories in Vietnam), India, Uganda, China and Bangladesh. Dr Pierce holds a PhD in Chemistry from University of North Carolina.
Executive Secretary - Dr Sonia R Pagliusi (non-voting)
Dr. Pagliusi has been the Executive Secretary of DCVMN International since 2011. She has over 25 years of professional experience in both private and public sectors, and worked with leading multinational pharmaceutical and biotechnology industries, and with WHO at the vaccines department. She holds a degree in Biomedical Sciences from Paulista Medical School, Brazil, Biochemistry a Diploma from Free University Berlin, a PhD in Molecular Biology from Heidelberg University and a Public Health Management degree from Geneva University.
AC Coordinator - Dr Maureen Dennehy (non-voting)
Dr. Dennehy is an independent consultant who provides, with associates, contract top-up and specialist services to pharmaceutical and medical device / biologicals manufacturers. She has also worked with DCVMN since 2015, and previously worked at Biovac and the State Vaccine Institute, South Africa. She has a PhD and MBA from the University of Cape Town, is an IRCA-certified auditor for Pharmaceutical Quality Management Systems (PQMS) and an ISPE Certified Pharmaceutical Industry Professional (CPIP).

Partners: